Blood-Based Biomarker Panel Plus Personalized Risk Model Improved Risk Assessment for Lung Cancer Screenings

Investigators reported that combining a blood-based biomarker panel with PLCOm2012 resulted in a significant improvement in risk assessment for lung cancer screenings. The combination of a blood-based 4-marker protein panel plus a personalized lung cancer risk prediction model (PLCOm2012) significantly improved risk assessment for lung cancer screenings, according to results from...